According to research published in Pediatric Blood & Cancer, brentuximab vedotin (BV) in combination with bendamustine appears to be safe and efficacious in pediatric patients with relapsed or refractory (R/R) Hodgkin lymphoma (HL).

“Although children and young adults with Hodgkin lymphoma usually have a favorable prognosis, patients with primary refractory disease and some subsets of relapsed patients still have a dismal outcome,” the authors wrote in their report.

To evaluate the role of BV with bendamustine as a suitable salvage therapy, the investigators conducted a retrospective analysis of toxicity and outcomes in pediatric and young adult patients with R/R HL who received the combination treatment with the aim of obtaining a durable remission as bridge to hematopoietic stem cell transplant (HSCT).

Continue Reading

Data on 32 patients (56% male and 44% female) treated between December 2013 and April 2019 were included in the study. Patients received up to 6 cycles of treatment with BV at 1.8 mg/kg on day 1 and bendamustine at 90-120 mg/m2 on days 2 and 3.

At the time of treatment, patients’ median age was 16 years (range, 8-25). Extranodal disease was present in 66% of patients. Among all patients, 53% had primary refractory disease, and 47% had relapsed disease. Patients had received a median of 2 prior chemotherapy regimens (range, 1-10), and 50% had received prior radiation therapy, while 16% had received either autologous or allogeneic HSCT. Prior BV had been given to 9% of patients, and single-agent bendamustine had been given to 1 patient.

Patients received a median 4 of treatment cycles (range, 2-6). The treatment was considered well tolerated and demonstrated a toxicity profile consistent with previously published data. The most common treatment-related adverse event was grade 3-4 hematologic toxicity in 44% of patients. Peripheral neuropathy (reversible in all cases) was observed in 9% of patients. No grade 5 treatment-related adverse events were observed.

After the first 2 treatment cycles, 28 of 32 patients (87.5%) underwent early response assessment. Of 28 patients, 15 (54%) had a complete remission (CR), and 13 (46%) had a partial response (PR). After the early response assessment, 2 deaths occurred (1 due to subsequent relapse and progression and 1 in CR due to transplant-related mortality following allogeneic HSCT). The remaining 13 patients are alive and remain disease free.

At the end of treatment, the overall response rate was 81%, with 22 patients (69% in CR and 4 patients (12%) in PR. The remaining 6 patients (19%) experienced progression/relapse. Among patients who obtained an objective response, 22 received consolidation with high-dose chemotherapy and subsequent autologous HSCT, and 4 underwent allogeneic HSCT (3 had a prior failed autologous HSCT and 1 due to medical decision).

At a median follow-up of 42 months (range, 11-94), the entire cohort had 3-year overall survival rate of 78.1%, progression-free survival rate of 67%, and disease-free survival rate of 62.3%.

“Our experience confirms that the combination of BV and bendamustine is a valuable therapeutic option in children and adolescent and young adults with R/R HL, both for heavily pretreated patients and in the first-line settings, offering a chance of achieving CR or disease control with manageable toxicity,” the investigators concluded. “[Our] results suggest that this treatment is a suitable option as a bridge to HSCT.”

The main limitation of the study was the retrospective design. The investigators noted that the findings need to be confirmed in a prospective clinical trial with more patients.


Vinti L, Pagliara D, Buffardi S, et al. Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma. Pediatr Blood Cancer. 2022;69(4):e29557. doi:10.1002/pbc.29557

This article originally appeared on Hematology Advisor